The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2022 | Where are we with CAR-T in CLL?
John Gribben, MD, DSc, FRCP, FRCPath, FMed Sci, Barts Cancer Institute, London, UK, talks on the current status of CAR-T therapy in chronic lymphocytic leukemia (CLL). T-cell dysfunction is a major barrier to developing CAR-T therapy for CLL. However, the introduction of ibrutinib has shown to have a great impact on the efficacy of CAR-Ts. Prof. Gribben shares his excitement for the potential approval of a CAR-T product in CLL. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
